Patient Characteristics
There were 141 patients screened and 88 patients randomized in the trial: 45 in the SOC group and 43 in the SOC plus disulfiram and copper group. Among the 88 patients randomized, the mean (SD) age was 55.4 (11.5) years; 63 (72%) were male, and 54 (61%) had Karnofsky performance status 90% to 100% at baseline. Three patients did not start any treatment within the trial and were excluded from the safety analysis. A total of 5 patients in the SOC group withdrew consent and were, together with patients not receiving any treatment, excluded from the per protocol (PP) population. The randomization and study populations are presented in 